Zalevsky Jonathan (CIK 1789857) reported 16 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-02). Recent activity: Sell NKTR (5,681 shares), Sell NKTR (5,538 shares), Sell NKTR (199 shares), Sell NKTR (180 shares), Sell NKTR (3,867 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 5,681 | $397,670 |
| 2026-06-17 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 5,538 | $336,212 |
| 2026-05-21 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 199 | $13,036 |
| 2026-02-20 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 180 | $13,140 |
| 2026-01-22 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 3,867 | $137,936 |
| 2025-12-23 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Buy | 6,250 | $0 |
| 2025-11-25 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Buy | 2,666 | $0 |
| 2025-11-25 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 1,157 | $62,802 |
| 2025-09-08 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 793 | $25,717 |
| 2025-09-08 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 432 | $14,515 |
| 2025-09-08 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 189 | $6,503 |
| 2025-09-08 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 307 | $10,957 |
| 2025-09-04 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 485 | $14,598 |
| 2025-08-21 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 725 | $19,278 |
| 2025-05-21 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 10,712 | $0 |
| 2025-02-21 | NEKTAR THERAPEUTICS (NKTR) | Chief R&D Officer | Sell | 10,300 | $0 |
Source: SEC Form 4 filings · as of 2026-07-02